US › Healthcare

BioXcel Therapeutics Inc (BTAI)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$0.05+2.00%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$182,000

Revenue YoY

+51.7%

Net profit

$-14.7M

EPS

$-0.49

EPS estimate

$-0.51

Net margin

-8,084.1%

EPS came in at -0.49 against a street estimate of -0.51 — a beat of 3.9%.

Key statistics

Market cap

$2.3M

Forward P/E

0.0

P/B

27.50

Book value

$-3.69

EPS (TTM)

$-2.58

52-week high

$3.19

52-week low

$0.02

50-day MA

$0.73

200-day MA

$1.30

Beta

0.19

Analyst view

Analysts rate BioXcel Therapeutics Inc a buy (2 buy, 0 hold, 1 sell out of 3) with an average price target of $21.50.

Shareholding

Insiders

3.60%

Institutions

25.99%

Largest institutional holders

Fund	Stake
Millennium Management LLC	6.76%
Armistice Capital, LLC	6.10%
Oaktree Capital Management LLC	0.77%
Geode Capital Management, LLC	0.74%
Vanguard Capital Management, LLC	0.66%
Citadel Advisors Llc	0.48%
JONES FINANCIAL COMPANIES LLLP	0.42%
Man Group PLC	0.31%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioXcel Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.